Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Diffuse gliomas represent a heterogeneous group of universally lethal brain tumors
characterized by minimally effective genotype-targeted therapies. Recent advances have …

Resistance to anticancer therapies includes primary resistance, usually related to lack of
target dependency or presence of additional targets, and secondary resistance, mostly …

In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …

The common mutation BRAFV600 in primary melanomas activates the mitogen-activated
protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the …

Gliomas are molecularly heterogeneous brain tumors responsible for the most years of life
lost by any cancer. High-grade gliomas have a poor prognosis and despite multimodal …

BRD4 is well known for its role in super-enhancer organization and transcription activation
of several prominent oncogenes including c-MYC and BCL2. As such, BRD4 inhibitors are …

PURPOSE Children with pediatric gliomas harboring a BRAF V600E mutation have poor
outcomes with current chemoradiotherapy strategies. Our aim was to study the role of …

BRAF mutations have been identified as targetable, oncogenic mutations in many cancers.
Given the paucity of treatments for primary brain tumors and the poor prognosis associated …

Background Detailed prevalence estimates of BRAFV 600 mutations and BRAF inhibitor
(BRAFi) treatment responses in V600-mutant glioma will inform trial development. Methods …